Early changes in dynamic biomarkers of liver fibrosis in hepatitis C virus-infected patients treated with sofosbuvir. Issue 3 (March 2016)

• Record Type: Journal Article
• Authors: Bernuth, Sebastian; Yagmur, Eray; Schuppan, Detlef; Sprinzl, Martin F.; Zimmermann, Anca; Schad, Arno; Kittner, Jens M.; Weyer, Veronika; Knapstein, Johanna; Schattenberg, Jörn M.; Wörns, Marcus A.; Galle, Peter R.; Zimmermann, Tim
• Is Part Of: Digestive and liver disease. Volume 48:Issue 3(2016)
• Page Start: 291
• Page End: 297
• Publication Date: 2016-03
• Subjects: ELF -- FibroScan -- Liver fibrosis -- Liver stiffness measurement -- Non-invasive serum markers; Digestive organs -- Diseases -- Periodicals; Liver -- Diseases -- Periodicals; 616.33005
• DOI: 10.1016/j.dld.2015.09.015
• Languages: English
• ISSNs: 1590-8658

Abstract

Abstract: Background: Chronic hepatitis C is a major cause of liver-associated mortality caused by decompensated cirrhosis and hepatocellular carcinoma. With the approval of sofosbuvir, therapeutic efficacy has markedly increased. Early changes in non-invasive biomarkers of liver fibrosis under effective antiviral therapy are widely unknown. Aim: To evaluate early changes of fibrosis markers determined by enhanced liver fibrosis (ELF) scores and liver stiffness measurement (FibroScan ® ) in patients treated with sofosbuvir. Methods: A total of 32 hepatitis C patients treated prospectively with sofosbuvir were included. The ELF-panel and FibroScan measurements were performed at baseline, week 4, end-of-treatment and 12 weeks thereafter. Results: Antiviral therapy resulted in a biochemical and virological response within 4 weeks. Sustained virological response rate at 12-week follow-up (SVR12) was 93.8%; there was a significantly decrease from baseline to 12-week post-treatment follow-up in ELF (10.00 vs. 9.37; p = 0.007) and FibroScan (8.0 vs. 6.8 kPa; p = 0.016) measurements, indicating improvement of the dynamics of liver fibrosis. Conclusion: We observed a rapid decrease in non-invasive fibrosis markers measured by ELF-scores and FibroScan in hepatitis C-infected patients receiving sofosbuvir treatment. These initial results need to be histologically confirmed by liver biopsy in the future.